Notes from Friedland's Interview:
1. "It's fascinating....The news announcement on Monday... a full patent application was filed with the US Patent office to replace the original patent on this claim. A lot of people have topical products out there But OWCP's psoriasis cream has undergone a huge amount of trials in Israel, and Israel is 95% of Cannabis research in the world.
2. Mark Leibovit: "OWC had many products on the pipeline, this psoriasis cream is just one of many."
3. Friedland: "Yes... the one I am most fascinated about is that OWC is doing some ore clinical work for Multiple Myloma. Nothing right now conventionally kills multiple myloma cancer cells and the preliminary results that they did with mice, in 60% of the mice, 100% of the Multiple Myloma cells were killed. It's not human trials but those are quite significant. What people have to understand about OWCP is that it's a pharmaceutical development company. They have to also understand that OWCP is about the Cannabis space in Israel and its scientists - and that's keys. OWC and it's management team over there are incredibly plugged into what's happening in Israel, which is leading edge on Pharma development worldwide.
4. Leibovit: "Jeff Friedland has been involved with the Cannabis space in Israel and USA (including cultivation facilities and dispensaries ie Colorado) for a long time."
5. Friedland: "I am delighted to be involved in the space in Israel, USA and Canada. I love this space. Israel is an emerging market."
6. Leibovit: "I am very excited too and the Médical Marijuana space offers a great opportunity for investors and helps a lot of people. This was not a paid interview, this was my love for the space."
